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Abstract
Protein misfolding is common across many neurodegenerative diseases, with misfolded
proteins acting as seeds for "prion-like" conversion of normally folded protein to abnormal
conformations. A central hypothesis is that misfolded protein accumulation, spread, and dis-
tribution are restricted to specific neuronal populations of the central nervous system and
thus predict regions of neurodegeneration. We examined this hypothesis using a highly sen-
sitive assay system for detection of misfolded protein seeds in a murine model of prion dis-
ease. Misfolded prion protein (PrP) seeds were observed widespread throughout the brain,
accumulating in all brain regions examined irrespective of neurodegeneration. Importantly,
neither time of exposure nor amount of misfolded protein seeds present determined regions
of neurodegeneration. We further demonstrate two distinct microglia responses in prion-
infected brains: a novel homeostatic response in all regions and an innate immune response
restricted to sites of neurodegeneration. Therefore, accumulation of misfolded prion protein
alone does not define targeting of neurodegeneration, which instead results only when mis-
folded prion protein accompanies a specific innate immune response.
Author Summary
Normal brain function requires tight regulation of protein folding; when this goes wrong,
proteins can fold into abnormal conformations, which have severe impacts on brain per-
formance, leading to conditions like dementia. Previous studies show that abnormally
folded proteins are found in restricted parts of the brain, and neuronal cells in these spe-
cific brain regions have been shown to undergo degeneration. Recent technological
advances have enhanced the detection of abnormally folded prion protein (PrP) during
disease; we used these technologies to test whether distribution of abnormally folded
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proteins is indeed restricted to regions of the brain undergoing degeneration. Surpris-
ingly, we observed abnormally folded proteins throughout the brain, demonstrating that
these proteins can accumulate in parts of the brain that do not show degeneration. Thus,
the distribution of abnormally folded protein, by itself, is not sufficient for neuronal
degeneration. In addition, we found that microglia (one of the nonneuronal cell types in
the brain) change their response during prion disease in two different ways; one response
is associated with resilient brain regions, and the second, an inflammatory response is
associated with regions susceptible to degeneration. Thus, the microglial response appears
to be important in determining the outcome of disease.
Introduction
Many chronic neurodegenerative diseases, such as Alzheimer disease, Parkinson disease and
Transmissible Spongiform Encephalopathies (TSE) or prion diseases, are characterised by
accumulation of misfolded proteins [1]. The appearance of detectable misfolded proteins and
their relationship to neurodegeneration have been the major focus for defining disease mecha-
nisms. However, it remains unclear what precise role misfolded proteins have in disease
pathogenesis.
The prion diseases provide valuable model systems to examine this relationship and define
mechanisms of neurodegenerative disease. The host protein is an absolute requirement for dis-
ease because, in the absence of prion protein (PrP), mice have been demonstrated to be resis-
tant to disease [2,3]. Furthermore, PrP-/- mice that have PrP+/+ tissue grafts into the brain have
demonstrated deterioration of PrP+/+ graft tissue but preservation of host PrP-/- neurons when
experimentally infected with a prion disease [4]. At clinical stages, misfolded protein aggre-
gates are usually detected in brain regions undergoing overt neurodegeneration. The accumu-
lation and aggregation of misfolded proteins precede detectable neurodegeneration [5–9].
Recent studies have suggested that the spread of a number of different misfolded protein spe-
cies between distinct brain regions occurs in a “prion-like” mechanism and is thought to deter-
mine specific brain regions that undergo neurodegeneration (reviewed in [10,11]). For
example, in Alzheimer disease, the initial detection of tau-neurofibrillary tangles in the locus
correleus and entorhinal cortex spreads in a pattern resembling interconnected brain regions
[12], which correlates with cognitive decline in patients. Initial detection of Amyloid-beta (Aβ)
is in the neocortex before spreading to allocortex and subsequently to subcortical regions in a
pattern that broadly corresponds to anatomical connections. These studies can lead to the con-
clusion that accumulation, spread, and distribution of misfolded proteins predict regions that
ultimately undergo neurodegeneration and thus define disease outcome. However, a number
of findings question the direct relationship between protein misfolding and neurodegenera-
tion. For example, misfolded PrP accumulates in the brain, in some situations unaccompanied
by other typical neuropathological changes or any clinical signs of disease [13–16]. This rela-
tionship is not clear in the other protein misfolding diseases because the accumulation of Aβ
as amyloid plaques, for example, has been detected in the brains of cognitively normal, aged
individuals [17]. Furthermore, the detection of Aβ in Alzheimer disease patients does not
always correspond to the anatomical regions accumulating neurofibrillary tangle lesions,
which, as mentioned above, correlate strongly with cognitive decline [12]. Taken together, this
raises the question as to the relationship between the appearance of misfolded protein aggre-
gates and neurodegeneration.
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Exquisitely sensitive methods have been developed for detection of misfolded PrP [18–20].
These methods test whether samples contain misfolded PrP isoforms, defined by their ability
to convert recombinant PrP to abnormal isoforms. The products are detectable using fluores-
cent amyloid fibril-binding compounds, such as thioflavin-T (ThT) [18,19], therefore testing
the capability of a sample to act as a “prion seed.” This therefore represents the detection of
only those misfolded PrP isoforms that can seed the conversion of normally folded PrP to mis-
folded isoforms that may be just a portion of the total misfolded PrP present. Although seeding
activity is unlikely to be the only important characteristic of pathological forms of PrP, it is an
important feature in as much as it reflects the fundamental principle of the self-propagating
potential of prions. The increased sensitivity of this assay, termed the real-time quaking-
induced conversion (RT-QuIC) assay, allows a novel approach to study the role of misfolded
protein, which can act as seeds, in relation to microglial and astrocytic responses and neurode-
generation. Moreover, the prion models allow precise time course studies to be conducted to
assess the presence of misfolded protein in specific regions of the brain from initiation of dis-
ease through to neurodegeneration.
We have used the RT-QuIC assay system to examine the distribution of prion seeds in
selected regions of the brain in a murine model of prion disease and compared this with the
spread of misfolded PrP using other detection systems such as immunohistochemistry (IHC),
neurodegeneration, and glial cell responses. We have established that the misfolded protein
alone is insufficient for neurodegeneration, and a complex and heterogeneous microglia
response is associated with disease.
Results
Misfolded PrP, Detectable Using IHC, Is Targeted to Specific Brain
Regions
In this study, the GSS/101LL model of prion disease was used [14]. This involves an intracere-
bral (i.c.) inoculation of a human Gerstmann-Stra¨ussler-Scheinker (GSS) brain homogenate
into mice that have a proline to leucine alteration at codon 101 of the murine PrP—henceforth
termed GSS/101LL. For controls, a normal brain homogenate (NBH) was inoculated i.c. into
age-matched mice (NBH/101LL). Animals were assessed daily for 2 wk by animal staff inde-
pendent to this study after inoculum injection to ensure condition and health of mice did not
deteriorate. The important feature of the GSS/101LL model for this study is the distinct and
restricted regions of pathology in the brain at the terminal stage of disease at 291 ± 5.3 days
post inoculation (dpi). To define the earliest detectable accumulation of misfolded PrP and its
relationship to neurodegeneration, serial sections were taken throughout the brain of GSS/
101LL and NBH/101LL mice at several points within the incubation period: 150, 200, 220, and
240 dpi, and terminal stage (291 ± 5.3 dpi).
Granular deposits of misfolded PrP were detected in the midbrain at 150 dpi by IHC (Fig
1). Specifically, the staining observed is associated with the interpeduncular nuclei and sub-
stantia nigra, pars compacta (SNc). No staining could be observed in any other brain region
(Fig 1); therefore, the initial IHC-detectable misfolded PrP targets specific midbrain nuclei. At
200 dpi, IHC-detectable misfolded PrP remained restricted only to midbrain nuclei. At later
time-points (>220 dpi), additional IHC-detectable PrP could also be detected in brain stem
regions such as the medial and dorsal raphe nuclei in GSS/101LL animals. No IHC-detectable
PrP was observed in any other brain region at this time-point. At clinical onset of disease, IHC
detection of misfolded PrP could be observed restricted to specific neuronal populations in
three major brain regions: the midbrain, brain stem, and thalamus (Fig 1). No IHC-detectable
misfolded PrP was observed in other brain regions.
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Widespread Distribution of Prion Seeds
We hypothesised that misfolded prion seeds would also be restricted to the specific brain
regions associated with IHC-detectable misfolded PrP and that these brain regions would
Fig 1. Detection of misfolded PrP using IHC at different time-points in different brain regions. (a) At 150 dpi, small quantities of fine-punctate
misfolded PrP deposits can be detected in the midbrain. This positive staining could be observed in five of twelve GSS/101LL mice tested, but no
staining was observed in any NBH/101LL animal in any brain region (n = 12). At 220 dpi, fine-punctate misfolded PrP deposits were detectable in both
the midbrain and brain stem, which was observed in four of six GSS/101LL mice tested, but no staining was observed in any NBH/101LL animal in any
brain region (n = 6). At clinical onset of disease (291.1 ± 5.3 dpi), misfolded PrP staining could be observed in midbrain, brain stem, and the thalamus
but not in cortex or cerebellum in GSS/101LL mice. This staining pattern was observed in all mice tested at this stage (n = 9), whereas no staining was
observed in any NBH/101LL animal in any brain region tested (n = 4). Scale bars: midbrain = 100 μm, brain stem, thalamus, cortex, and
cerebellum = 200 μm. (b) Quantification of PrP+ staining intensity. The levels of PrP+ staining are originally high in the midbrain, but at later time-points
in other brain regions, such as brain stem and thalamus, the levels of PrP+ staining increase to comparable levels to that of the midbrain. In cortex and
cerebellum, no change in PrP+ staining was observed. Quantitation was performed using colour deconvolution plug-in to Image-J software.
doi:10.1371/journal.pbio.1002579.g001
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specifically undergo neurodegeneration, whereas those with no immunopositive PrP deposits
would contain no prion seeds and remain free of neurodegeneration. In order to test this
hypothesis, four brain regions were assessed for the presence of prion seeds as defined by their
ability to act as seeds in the RT-QuIC assay and generate a ThT-positive signal. These were
two IHC-positive regions the brain stem (between Bregma -6 to -8) and thalamus (between
Bregma -1 to -3) and two IHC-negative regions the cerebellum (between Bregma -6 to -8) and
cerebral cortex (between Bregma -1 to -3) (henceforth referred to as cerebellum, brain stem,
thalamus, and cortex). All of these brain regions from GSS/101LL mice, when used in the
RT-QuIC assay, elicited an increased ThT fluorescence not observed in uninfected NBH con-
trols (Fig 2A). Thus, the increased level of fibril formation was specific to prion infection and
Fig 2. RT-QuIC shows widespread detection of misfolded prion seeds beyond levels detected using IHC. (a) ThT fluorescence readout over
time during the RT-QuIC assay. Each solid line represents a GSS/101LL brain region, whereas each dotted line represents a NBH/101LL brain region.
These data are comprised of the averages from triplicate RT-QuIC reactions from three separate repeat experiments collected from four separate GSS/
101LL dissected brains and five NBH/101LL dissected brains all at the terminal stage of disease (291.1 ± 5.3 dpi). The different brain regions are colour
coded to illustrate the brain stem (red), thalamus (blue), cerebellum (purple), and cortex (green) for both the GSS/101LL and NBH/101LL samples. (b)
RT-QuIC ThT fluorescence readout at 48 h (respective to cycle 190 in the RT-QuIC assay) using samples with or without PK exposure. ThT
fluorescence increases are observed in each PK-exposed brain region of GSS/101LL mice (n = 4), showing that the misfolded PrP responsible for the
seeding event has obtained a PK-resistant conformation in all GSS/101LL brain regions. No increase in ThT fluorescence was observed in NBH/101LL
control brain regions (n = 5), demonstrating the specificity of prion seeding ability in GSS/101LL brain regions. GSS/101LL samples are presented as red
(brain stem), blue (thalamus), purple (cerebellum), or green (cortex), and region-matched NBH/101LL controls are plotted in the same columns as grey
open dots. These data are comprised of triplicate RT-QuIC reactions for each brain region of each animal tested.
doi:10.1371/journal.pbio.1002579.g002
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demonstrated the presence of prion seeds in each brain region tested. To assess whether the
prion seeds detected in these brain regions represented a protease-resistant conformational
rearrangement of PrP [21], proteinase K (PK) digestion was performed on all samples of brain
regions prior to their inclusion in the RT-QuIC assay. In all regions from prion-infected brains
exposed to PK, prion seeds remained detectable, but PK-resistant prion seeds were not
observed in any region of age-matched uninfected NBH controls (Fig 2B). To confirm the
widespread appearance of prion seeds, we have tested these same brain regions that gave posi-
tive RT-QuIC detection in a different assay: the protein misfolded cyclic amplification
(PMCA) assay [22]. We show that, similar to RT-QuIC, all brain regions from GSS/101LL
tested were capable of seeding the PMCA reaction (S1 Fig), conclusively demonstrating the
widespread accumulation of misfolded PrP, which can act as prion seeds in all brain regions
tested in GSS/101LL mice.
Prion Seed Accumulation Is Not Always Linked with Neurodegeneration
We performed an IHC analysis on the four regions from the prion-infected brains that were
positive for prion seeds using the RT-QuIC (Fig 2; brain stem, thalamus, cortex, and cerebel-
lum). Previous studies have demonstrated morphological changes associated with microglial
activation and astrogliosis as valuable histological markers for early pathology, as both occur
early in the course of disease before other early pathological changes as observed via histology,
such as synaptic degeneration [23–27]. At clinical disease stage, we observe activated micro-
glial and astrocyte glial cell responses. These are characterised by an up-regulation of glial-
fibrillary acidic protein (GFAP), indicative of reactive astrocytes, or the hypertrophy of micro-
glial cell bodies and thickening of microglial cell processes detected with Ionised calcium-
binding adapter molecule 1 (Iba1) indicative of activated microglia. These glial cell responses
were observed specifically restricted to brain stem and thalamus in GSS/101LL animals (Fig 3)
but were not seen in cortex or cerebellum of GSS/101LL animals or in any NBH/101LL brain
region (Fig 3).
Midbrain neurons were assessed by their expression pattern of tyrosine hydroxylase, and
no change in its staining pattern could be detected until clinical onset of disease (Fig 4A), at
which point significant cell loss was observed (Fig 4E). Cell loss was also quantified in specific
neuronal populations in the brain stem and cortex and showed substantial cell loss in the brain
stem but not in the cortex (Fig 4E). Brain stem, thalamus, cortex, and cerebellum neurons
were assessed using antibodies against microtubule associated protein 2 (MAP2), isoforms a
+b. No change in MAP2 staining could be observed in cerebellum or cortex neurons at clinical
stages of disease (Fig 4B and 4F). Substantial changes in MAP2 staining were observed in brain
stem nuclei, such as the gigantocellular reticular nuclei (Fig 4B, 4C and 4F). This encompassed
a general loss in precise cell body–associated staining compared to region- and age-matched
NBH/101LL controls, which is indicative of neuronal degeneration in GSS/101LL brain stem.
A reduction of MAP2 staining associated with dendritic processes was observed in the thala-
mus at clinical stages of disease, which was particularly prevalent in the ventral-medial parts of
the thalamus (Fig 4B and 4F). To further assess specific neuronal populations of the cerebel-
lum, antibodies specific to the calcium-binding protein parvalbumin were used. Parvalbumin
is highly expressed in Purkinje and stellate and basket neurons of the cerebellum and has been
shown to be lost as a result of pathology in the cerebellum [28]. No change in the pattern of
staining or intensity was observed in the GSS/101LL cerebellum compared to uninfected con-
trols, even at clinical stages of disease (Fig 4D).
Finally, we analysed the presence of spongiform vacuolation of the neuronal parenchyma,
which is a pathology commonly associated with prion disease and is quantified using well-
Misfolded Prion Protein Seeding Does Not Predict Regions of Neurodegeneration
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Fig 3. Morphological glial cell responses are restricted to specific brain regions. (a) Severe astrogliosis is
observed in the brain stem and thalamus of GSS/101LL but is not detected in NBH/101LL age-matched controls or
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established protocols, which we followed in our study [29]. We observed very low levels of vac-
uolation in most areas of the brain that were analysed, with the highest levels of vacuolation
being observed in the medulla (brain stem) and negligible levels found in cerebellum or
in the cortex or cerebellum of GSS/101LL mice. (b) High magnification image demonstrating the change in
astrocyte expression of GFAP in GSS/101LL mice compared to equivalent NBH/101LL brain regions. (c) A distinct
change in cell morphology to that of a hypertrophied cell body and short thick processes could be observed in Iba1
+ cells, indicative of activated microglia, in GSS/101LL brain stem and thalamus. No change in cell morphology was
observed in either NBH/101LL age- and region-matched control samples or in GSS/101LL cortex and cerebellum
samples. (d) High magnification image to highlight the shortening and thickening of microglial processes, a
characteristic common to morphologically activated microglia. These findings are observed consistently across all
animals tested; GSS/101LL (n = 9), NBH/101LL (n = 4). Scale bars = 100 μm.
doi:10.1371/journal.pbio.1002579.g003
Fig 4. Changes in neuronal markers demonstrate specific neuronal populations targeted to certain brain regions. (a) Tyrosine
hydroxylase staining of midbrain neurons. No visible change in staining pattern could be observed in any GSS/101LL animal tested at 240 dpi
(n = 6) compared to age- and region-matched NBH/101LL controls (n = 6). A marked loss of staining pattern is observed in the midbrain neurons
upon clinical onset (291.1 ± 5.3 dpi), indicative of a loss of tyrosine hydroxylase neurons upon clinical onset of disease. Scale bar = 200 μm. (b)
MAP2 staining in brain stem has marked loss of MAP2 cell–associated staining compared to NBH/101LL brain stem age-matched control. Overall,
levels of MAP2 staining are visibly lost in the ventral-medial parts of the thalamus compared to region- and age-matched NBH/101LL controls. No
change could be observed in the staining pattern of MAP2 in any part of the cortex or cerebellum compared to region- and age-matched NBH/
101LL controls. These findings are observed consistently across all animals tested; GSS/101LL (n = 9), NBH/101LL (n = 4). Scale bars = 100 μm.
(c) Higher magnification examples of MAP2 neurons lost in the gigantoreticular nuclei of the brain stem but no loss of neurons evidenced in the
cortex. (d) Parvalbumin staining of Purkinje cells of the cerebellum at clinical stages of disease in GSS/101LL animals (291.1 ± 5.3 dpi; n = 3)
compared to age-matched NBH/101LL controls (n = 3). Scale bars = 100 μm. (e) Neuronal cell counts of substantia nigra (SN) neurons of the
midbrain, gigantocellular reticular nuclei (Gi) of the brain stem, and retrosplenial granular region (RSGc) of the cortex from three representative
animals. Cells counted based upon the number of cells showing positive staining for either tyrosine hydroxylase (TyHy+) in the SN or MAP2 in the
Gi and RSGc. (f) Quantification of MAP2+ staining intensity from three representative animals showing a loss of MAP2 staining in brain stem and
the thalamus but no change in the cortex or cerebellum. Quantification of staining was performed using colour deconvolution plug-in of Image-J
software.
doi:10.1371/journal.pbio.1002579.g004
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cortical regions (S2 Fig). Taken together, these data show that neurodegeneration and mor-
phological glial cell responses are restricted to the brain stem and thalamus, whereas cortex
and cerebellum appear to remain pathologically “unaffected,” even at clinical stages of disease.
Absence of Overt Neurodegeneration Is Not Due to Time of Exposure or
Differing Levels of Prion Seeds
Several arguments could be made to explain the apparent lack of neurodegeneration in regions
exposed to prion seeds, such as the following: (i) the amount of prion seeds may vary between
regions undergoing neurodegeneration and regions that appear unaffected; (ii) tissue under-
going neurodegeneration may have been exposed to prion seeds for comparatively longer peri-
ods of time than regions that remain unaffected; or (iii) prion seeds are necessary, but not
sufficient, for neurodegeneration. To address scenario (i), we ran the RT-QuIC assay with
decreasing concentrations of homogenate from each brain region to determine at what dilu-
tion detection of prion seeds is lost. Prion seeds were observed to support generation of a ThT
signal at a concentration of at least 10−5 of original brain homogenate, or 0.001% (w/v) of orig-
inal sample mass (Fig 5A). Thalamus, cerebellum, and cortex all showed an increased ThT
fluorescence at a concentration of 10−6 (0.0001% w/v of original sample mass). These data
show no relationship between quantity of detectable prion seeds and neurodegeneration, as
defined in Figs 3 and 4. To address scenario (ii), we tested for prion seeds at all time-points
used in this study (150, 200, 220, and 240 dpi and terminal illness). At 200 dpi onwards, an
increased ThT fluorescence was observed in brain stem and thalamus, which eventually suc-
cumb to neurodegeneration (Fig 5B), and in cerebellum, which does not undergo neurodegen-
eration (Fig 5B). This is reaffirmed at later time-points, with increased ThT fluorescence also
observed in GSS/101LL cortex samples (Fig 5B). The data show that detectable prion seeds
become widespread at relatively early but specific stages of disease progression but appear not
to be associated with resilience or susceptibility of a particular brain region to
neurodegeneration.
Transcriptional Response to Accumulation of Prion Seeds in the
Presence or Absence of Neurodegeneration
A transcriptomics analysis was performed on the four brain regions to help define host
responses to misfolded PrP in the presence or absence of neurodegeneration. Mice were sepa-
rated into three groups, with two mice per-group; RNA was extracted from individual brain
regions, and each group was pooled together. To interpret the microarray data, we used the
network analysis tool BioLayout Express3D [30] in combination with statistical methods. Fol-
lowing data normalisation, the software calculates a pairwise Pearson correlation matrix com-
paring the expression profile of each transcript represented on the array to the expression
profile of all other transcripts. All correlations above a user-defined threshold are used to con-
struct a network graph visualised in 3-D space. When groups of genes are similarly expressed,
they are tightly correlated and give rise to highly connected cliques within the network. This
structure is used by the Markov clustering algorithm to divide the graph into clusters of co-
expressed transcripts [31]. The network topography of our data produced three groups of
genes (components A–C), which do not share direct correlation between one another. Within
each component, there are several distinct clusters of highly correlated genes (Fig 6A). The
major clusters of genes in component A (e.g., clusters 1, 3, and 6) show differential gene
expression between brain regions but have no obvious relationship to disease (Fig 6) and
therefore were not examined further. However, components B and C both contain disease-
Misfolded Prion Protein Seeding Does Not Predict Regions of Neurodegeneration
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Fig 5. Neither quantity nor time of exposure of misfolded prion seeds are responsible for restricted neurodegeneration. (a)
RT-QuIC titration of brain region homogenates (n = 4) shows that all brain regions dilute to a concentration of at least 0.001% (w/v) of the wet
sample weight (10−5). Data shown are the average ThT fluorescence levels after 60 h incubation in RT-QuIC of triplicate RT-QuIC reactions.
Grey open dots represent NBH/101LL region-matched controls. (b) RT-QuIC run on GSS/101LL brain regions at several time-points
throughout the incubation period. Each sample was run at a concentration of 0.1% (w/v) of the wet sample weight (10−3) for n = 5 GSS/
101LL and NBH/101LL mice at each time-point, with exception of clinical (terminal) stage of disease (n = 4) and run in triplicate RT-QuIC
reactions. Grey open dots demonstrate average ThT fluorescence of NBH controls (n = 5) at each time-point. Data shown are the ThT
fluorescence levels after 48 h incubation in RT-QuIC.
doi:10.1371/journal.pbio.1002579.g005
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specific clusters (Fig 6). Component B contained the largest group of disease-associated genes,
and further analysis concentrated on this group.
Up-Regulation of a Large Group of Genes across All Brain Regions Can
Be Attributed to a Microglial Response
Data from component B were filtered stringently by first removing transcripts not annotated
to known or predicted protein coding regions of the genome. Annotated genes were then fil-
tered by Mann–Whitney U test (p 0.05) to define significantly altered genes by comparison
Fig 6. All GSS/101LL brain regions show disease-associated gene expression changes. (A) Biolayout Express3D
graph showing a spatial representation of genes orientated according to their correlation to one another. Three major and
separate components of highly correlated genes were formed using this software, which we term components A–C. This
structure was used by the Markov clustering algorithm to divide the graph into clusters of co-expressed transcripts, which
are shown in the graph as different colours. Representative clusters, shown as numbers 1–6, are shown on the graph,
which highlights the expression differences found between each of the three major components identified. These can be
viewed as average gene expression as bar graphs (B). (C) Filtered gene lists from the GSS/101LL cerebellum, thalamus,
and brain stem are overlaid onto the original graph. Shown here are the filtered genes highlighted in yellow (cerebellum),
purple (thalamus), or turquoise (brain stem) as part of component B of the main graph shown in (A). The highlighted genes
in each brain region were observed predominantly within the same part of the graph rather than segregating into distinct
groups, demonstrating that these differentially expressed genes between brain regions were highly correlated.
doi:10.1371/journal.pbio.1002579.g006
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of GSS/101LL brain regions to their respective NBH/101LL-matched control brain regions.
Furthermore, of those statistically significant genes, only those that exhibited a >1.5-fold
change between control and disease were analysed further. This group of genes exhibited an
increase in gene expression across all brain regions, with the greatest increases observed in
regions of neurodegeneration (brain stem and thalamus) and lower but significant increases in
gene expression in brain regions that do not show neurodegeneration (cerebellum and cortex)
(Fig 7A). Within component B, only a few significant gene expression changes were noted in
the cortex (11 genes) compared with a much larger number in the other regions, and therefore
the cortex was not included in further analyses in the current study.
To determine the cellular origins of component B, the filtered gene list was overlaid onto
previously published expression datasets of isolated cell populations. This included a variety of
murine myeloid populations (including microglia) [32] and brain cell populations (neurons
Fig 7. Disease-associated gene expression changes can be predominantly attributed to microglia in all GSS/101LL brain regions tested. (a) Spider
graph representation of component B genes after filtering. Up-regulation of genes in all GSS/101LL brain regions, but particularly increased in GSS/101LL
brain stem and thalamus compared to GSS/101LL cerebellum and cortex. N = number of genes present after data are filtered that constitute the average
intensity value. The number of genes represented is highest in GSS/101LL brain stem but lowest in GSS/101LL cortex. (b) Gene expression can be attributed
to specific cell types when overlaid onto previous microarray datasets. These data show a simplified version to demonstrate how different genes that are
known to have selective expression in specific cell types in vivo can be attributed to their expected cell type. For example, Cd11b is a gene generally regarded
as a pan-macrophage marker, and hence we show the increased expression of this gene in macrophage/microglial cell populations compared to other cell
types. Colony-stimulating factor 1 (Csf1) is a gene that is up-regulated during immune cell activation, shown here by its increased expression in
lipopolysaccharide-activated macrophages. Gfap is a gene expressed highly in astrocytes, and, indeed, we show the high and specific expression of Gfap in
astrocytes in this dataset. Finally, synapsin I is a synaptic-specific protein and therefore will most commonly be expressed in neurons, as is shown here. (c)
Attribution of genes that are identified in component b to their respective cell type shows that a majority of genes that are identified in component b can be
attributed to macrophage/microglia. (d) Representation of the macrophage/microglia gene list overlap of different brain regions tested.
doi:10.1371/journal.pbio.1002579.g007
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and glial cells) [33]. Using these datasets, in many cases we could attribute expression of spe-
cific genes to cell type of origin (Fig 7B). The majority of up-regulated genes in the brain stem,
thalamus, and cerebellum could be attributed to cells from a myeloid lineage and therefore
most likely derived from the resident microglia population (Fig 7C). Thus, the microglial
response appears to be an important host response in disease, with expression changes evident
in regions with and without IHC detectable glial cell changes (Fig 3A). The specific genes
attributed to microglia were sorted according to gene overlap (Fig 7D), showing distinct
groups of genes that have differential expression in specific brain regions.
To broaden our analysis of this pattern of distinct groups of genes, we next examined the
total microarray dataset, filtered according to the same statistical and fold-change parameters
outlined above (p 0.05; >1.5-fold change) and attributed to predicted cellular origin (S1
Table). Gene ontology (GO) enrichment of the microglial gene lists was assessed in two
groups: (1) genes not directly associated with neurodegeneration (i.e., all microglial genes
identified as up-regulated in the cerebellum) and (2) genes associated with neurodegeneration
(i.e., all microglial genes up-regulated in brain stem and thalamus but not differentially
expressed in cerebellum). Amongst the microglial genes up-regulated but not directly associ-
ated with neurodegeneration, the major GO terms relate to metabolism and regulation of
homeostasis (S2 Table). This demonstrates a response of microglia, which they are known to
exhibit, but has never, to our knowledge, been observed in chronic neurodegenerative diseases.
In genes up-regulated in brain regions undergoing neurodegeneration, significantly enriched
GO terms are related to activation of the innate immune response, complement activation,
and antigen processing and presentation (S3 Table), which concurs with previous data, sug-
gesting the innate immune response as an important and necessary component of the neuro-
degenerative process.
Discussion
We have demonstrated that, during the evolution of prion disease, prion seeds are widespread,
accumulating in brain regions both with and without overt neurodegeneration. We show that
the quantity or time of exposure to prion seeds was not directly related to the development of
neuropathology. Therefore, these pathological differences are not due to a lack of spread and
accumulation of prion seeds, indicating that prion seed accumulation is not itself sufficient for
neurodegeneration, at least within the lifetime of the mouse.
This extensive and widespread distribution of prion seeds has not been previously
described, and the highly sensitive assay developed for the detection of misfolded PrP has
allowed us to further investigate our understanding of the relationship of misfolded PrP and
neurodegeneration. In this study, we performed an i.c. inoculation that results in widespread
dispersion of the homogenate and its rapid degradation and clearance [34]. RT-QuIC detec-
tion of prion seeds from GSS/101LL mice was not increased over NBH/101LL age-matched
controls at 150 dpi; therefore, the RT-QuIC assay is detecting specific murine replication and
accumulation of misfolded protein at later time-points and not the initial human inoculum.
As a result, the RT-QuIC provides a highly sensitive assay system for examining the prion seed
accumulation and its interactions over the course of disease.
We show that detection of misfolded PrP using IHC is restricted to specific brain regions
undergoing neurodegeneration and associated morphological glial responses. Specific brain
regions, for example, the thalamus, only accumulate IHC-positive misfolded PrP at late stages
of disease (291 ± 5.3 dpi), whereas prion seeds are detected three months earlier in this region
(200 dpi). Some authors have asserted that misfolded protein aggregates are responsible for
causing neurodegenerative diseases and that the targeting of neurodegeneration is influenced
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by the restricted distribution of misfolded protein between brain regions [35,36]. These studies
rely on detection of misfolded proteins using techniques such as IHC or basic histology stain-
ing with silver staining (reviewed in [10]). In this study, by using an alternative and highly sen-
sitive method for the detection of misfolded PrP, which act as prion seeds, we find the
distribution of misfolded PrP seeding material does not predict the regions of
neurodegeneration.
IHC has been used extensively in prion disease as a terminal marker of the pathology in the
brain. Although, in time course studies, PrP IHC can be detected earlier in the disease process,
we believe the more sensitive assay systems (RT-QuIC and PMCA) are capable of detecting
the earlier events that ultimately lead to the IHC-detectable protein. Thus, the sensitive assays
both demonstrate that the pathways of protein misfolding are activated in all brain regions.
Although uncertainties remain about the exact nature and toxicity of the abnormal PrP that is
detected by IHC, the same can be said of RT-QuIC and PMCA. The use of sensitive techniques
has uncovered the novel finding that these pathological differences are not due to a lack of
spread and accumulation of prion seeds; rather, they correlate with local cellular differences in
the responses to those seeds that govern whether those seeds lead to bulk PrP accumulation
and pathological lesions. Although seeding activity is not likely to be the only important char-
acteristic of pathological forms of PrP, it is likely to be one of the most important features in as
much as it reflects the self-propagating potential of prions.
The question remains as to why only specific regions of the brain succumb to neurode-
generation. Previous studies have shown that the same prion strain inoculated into different
murine genetic backgrounds, which exhibit comparable quantities of detectable prion
seeds, can result in different sized aggregates of misfolded protein [37]. Just as large prion
particles have been shown to have lower infectivity per unit mass of PrP, i.e., specific infec-
tivity [38], so might larger prion seed particles be expected to have lower seeding activity
per mass than smaller particles. If so, then two regions could have the same seed concentra-
tion but divergent total loads of abnormal PrP. In addition, if the seeds are more clustered
in one brain region than another, they would also be more likely to be detectable by IHC. If
different types of aggregates are accumulating across brain regions, this is likely to impact
on production and clearance of aggregates in each region, with the type of misfolded pro-
tein being the driver of the response. An alternative explanation is that different regions of
the brain have differing abilities to respond to the same aggregates due to intrinsic variabil-
ity in gene expression of cells present. A specific example would be the underlying differ-
ences in microglial gene expression between brain regions in healthy young and aged
brains, which might underlie the specificity of microglial response during disease [39].
Thus, regional differences in protein aggregate and/or cell signalling could influence target-
ing of neurodegeneration.
We analysed transcriptional responses in each brain region and showed that the major
response in each brain region tested could be attributed to microglia, similar to previous
microarray studies on prion disease cases in human and animals [40–44]. Functional anno-
tation of the microglial response to misfolded protein, but in the absence of neurodegenera-
tion, revealed a large proportion of genes related to regulation of homeostasis. This
highlights a disease-specific response of microglia up-regulating a core set of genes, the key
function of which may be to respond to changes associated with protein misfolding. How-
ever, differential activation of the innate immune response is also observed in brain regions
undergoing neurodegeneration. These data suggest at least two distinct microglial responses
occurring during disease. In one, microglia respond to either the protein misfolding and/or
the consequences of protein misfolding by attempting to maintain homeostasis. In the
other, in regions of neurodegeneration, microglia up-regulate an innate immune response,
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which includes pro- and anti-inflammatory genes, complement activation, and antigen pro-
cessing and presentation.
The data presented here demonstrate that the seeding and distribution of misfolded protein
are more widespread at earlier time-points than previously described. Importantly, this seed-
ing occurs in brain regions that do not undergo neurodegeneration. We show that there is a
significant host response in all brain regions examined either in the presence or absence of
neurodegeneration. These responses are predominantly associated with microglial cells, and
functional annotation demonstrates distinct responses from these cells between brain regions
accumulating misfolded protein seeds either in the presence or absence of neurodegeneration.
Therefore, microglia appear to be on the one hand attempting to restore homeostasis intro-
duced by misfolded proteins that act as seeds, but in regions of neurodegeneration, the micro-
glia enter into a cycle of innate immune activation. Previous studies have demonstrated that,
by altering specific aspects of the innate immune response by KO of specific pro- or anti-
inflammatory genes, the severity of disease can be altered [45–51]. Furthermore, by inhibiting
microglial proliferation during disease, and thus reducing the number of microglia exhibiting
an activated innate immune response, other studies have shown a prolongation of incubation
period in prion disease [52]. Although it remains unclear what signals microglial cells are spe-
cifically responding to, specific misfolded protein isoforms or neurodegeneration, data from
previous studies together with data presented here could point to a role for the activation of
the innate immune response in defining severity of disease, which may contribute to the
destruction of cells in specific brain regions. Therefore, manipulation of the activation state of
microglia could represent a therapeutic target for suppressing neurodegeneration during dis-
ease (Fig 8). In summary, we find that the pathological differences between brain regions dur-
ing chronic neurodegeneration are not due to a lack of spread and accumulation of prion
seeds; rather, they correlate with local cellular differences in the responses to those seeds that
govern whether those seeds lead to bulk PrP accumulation and pathological lesions. A com-
bined approach characterising the host responses to the misfolded protein accumulation and
distribution, therefore, is required to more precisely determine the relevance of particular mis-
folded protein species to disease outcome.
Materials and Methods
Ethics
All experiments were approved by the Roslin Institute Ethical Review committee and in accor-
dance with the United Kingdom Home Office Regulations (Animals [Scientific Procedures]
Act of 1986). Ethical consent for the use of human materials for research was obtained and
approved by the Lothian National Health Service Board Research Ethics Committee (refer-
ence: 2000/4/157).
Animal Husbandry
The “101LL” transgenic mouse line contains an amino acid alteration from proline to leu-
cine at codon 101 of the 129/Ola (129/OlaHsd, Harlan, UK) murine prion gene by gene-tar-
geting [53]. 129/Ola mice homozygous for the targeted allele were crossed and bred over
multiple generations to generate progeny homozygous for the PrnpP101L (101LL) allele,
which can be used for experimental purposes. All mice were bred at the Roslin Institute
under a temperature-controlled, 12 h light/12 h dark cycle. Mice were housed with wood
chip bedding and a wood chew stick for environmental enrichment. Food and water were
available ad libitum.
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Genotyping
To confirm the presence of the targeted allele alteration, mice were genotyped before and after
studies. DNA extraction was performed using DNeasy Blood and Tissue kit (Qiagen) on ear
clips. Presence of the 101LL mutation was determined by PCR analysis using a primers specific
for positions 107–130 and 871–848 of the PrP gene; the 50 primer used was (50-ATGGCGAA
CCTTGGCTACTGGCTG–30; DDBJ/EMBL/GenBank accession number M18070), and the 30
primer used was (50–TCATCCCACGATCAGGAAGATGAG–30; DDBJ/EMBL/GenBank
accession number M18070). PCR was set up using a Type-it mutation detection kit (Qiagen).
PCR cycle conditions were as follows: 94˚C for 3 min, followed by 30 cycles of 94˚C for 30 sec,
62˚C for 30 sec, and 72˚C for 1 min. A final extension phase of 72˚C for 10 min was per-
formed, and samples were subsequently stored at 4˚C. The induced alteration of proline to leu-
cine in 101LL mice forms a DdeI restriction enzyme cut site, which allows for identification of
Fig 8. Microglial-neuron communication may define the relative resilience or susceptibility of neurons to
degenerate. Microglia are known to survey the neuronal parenchyma and interact intermittently with all parts of the
neuron. The accumulation of misfolded PrP, and potentially the different types of aggregates, will have an impact on
the communication and interaction between neurons and microglia. As a result, we observe different microglial
responses during disease as well as selective vulnerability of neurons to degenerate in specific brain regions. It
remains unclear whether the physiological differences of neuronal signalling, the known gene expression
differences of microglia between brain regions [37], or the different types of misfolded PrP aggregate are
responsible for the different microglial activation states. Based on the associations between the different microglial
activation states, the restricted neurodegeneration observed, and current knowledge of the importance of innate
immune activation in defining severity of neurodegeneration, we speculate that the different microglial activation
states could be defining neurodegeneration between different brain regions. This could either occur as a protective
microglial response in regions showing resilience to neurodegeneration or a contributor to neurodegeneration in
susceptible regions, or both. Our study highlights the need to further understand the basis for different microglial
activation states, which could allow future studies to manipulate microglial responses from a primed activated state
to one that regulates homeostasis and, thus, could represent a vital therapeutic target for intervention during
disease.
doi:10.1371/journal.pbio.1002579.g008
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101LL homozygous mice. The PCR product was incubated for 3 h at 37˚C with DdeI restric-
tion enzyme (Promega) before being run on a 1.5% agarose gel (Invitrogen) and imaged.
Prion Inoculum and Challenge
Human frontal cortex from a patient with GSS carrying the PRNP-P102L mutation was obtained
from the CJD Brain and Tissue Bank (Edinburgh Brain and Tissue Banks). The tissue was
homogenised in 0.9% sterile saline (Martindale Pharmaceuticals, UK) to a 1% (w/v) homoge-
nate, and mice were injected i.c. into the right hemisphere with 20 μL of 1% homogenate
under anaesthesia. Due to the difficulty in obtaining uninfected human tissue as a negative
control, an i.c. injection of 20 μL uninfected hamster brain homogenate (1% w/v) was per-
formed instead. These protocols were used to replicate those of previous studies using this
model of prion disease [14]. These form the GSS/101LL and NBH/101LL groups, respectively,
which are referred to throughout the text. All animals were aged-matched and were injected
between 10–14 wk of age. A time-course analysis was set up in this study, ranging from 150
dpi (GSS/101LL n = 12; NBH/101LL n = 12), 200 dpi (GSS/101LL n = 12; NBH/101LL n = 12),
220 dpi (GSS/101LL n = 6; NBH/101LL n = 6), 240 dpi (GSS/101LL n = 6; NBH/101LL n = 6),
and upon clinical symptoms of disease (GSS/101LL n = 9; NBH/101LL n = 12). All animals
were assigned to groups and assessed daily from around 100 dpi by an independent researcher
to this study using parameters that have been previously described [54]. All mice were killed
by CO2 asphyxiation according to Schedule 1 of the Animals (Scientific Procedures) Act of
1986.
Preparation of Tissue for Analysis
The brains of 101LL (GSS/101LL and NBH/101LL) mice were removed and halved along the
midline between the right and left brain hemispheres. The left hemisphere was flash frozen in
liquid nitrogen and stored at -80˚C for later use. The right hemisphere, which contains the
injection site, was immersion fixed in 10% formal saline for 48 h before being exposed to 98%
formic acid for 90 min to minimise the infectious titre of the sample. The tissue was subse-
quently re-washed in 10% formal saline for at least 24 h to remove residual formic acid. The
tissue was cut into five coronal sections for vacuolation scoring [29], which encompasses nine
grey matter (GM) regions (medulla, cerebellum, superior colliculus, hypothalamus, thalamus,
hippocampus, septum, rerospinal cortex, and cingulate and motor cortices). Tissue was then
paraffin embedded. Haematoxylin and eosin (H&E) staining of 6-μm sections were taken for
vacuolation (spongiform) severity scoring, which was performed blind by a researcher inde-
pendent to this study. For further pathological analysis, serial 10-μm sections were cut through
the brain.
Immunohistochemistry
Paraffin-embedded tissue was dewaxed by immersing in xylene and re-hydrated through a
series of decreasing alcohol concentrations at room temperature. For PrP immunostaining,
slides were immersed in citric buffer (0.1 M citric acid, 0.1 M Sodium Citrate, pH 6.4) and
autoclaved at 121˚C for 15 min. Slides were then cooled in running water for 5 min before
immersing in 98% formic acid for 10 min. Subsequently, slides were thoroughly washed in
running water for 20 min. To block for endogenous peroxidase, slides were immersed in 1%
H2O2/methanol before washing in running water for 5 min followed by PBS/1% BSA wash
buffer for 5 min. Sections were subsequently incubated with Normal Goat Serum (Stratech)
for 20 min before application of either BH1 ([55] used at 0.02 μg/mL) or 6H4 (Prionics used at
3 μg/mL) anti-PrP antibodies. The primary antibodies were incubated overnight before
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washing with PBS/1% BSA wash buffer. Goat anti-mouse secondary antibody (Jackson Immu-
noResearch) was applied for 1 h, washed in PBS/1% BSA, and ABC kit (Vector Laboratories)
was applied for 30 min then washed. Peroxidase activity was visualised using diaminobenzi-
dine (DAB):H2O2 and slides were counterstained in Harris’ haematoxylin.
For the immunohistochemical detection of other proteins, sections were either given no
antigen-retrieval step (e.g., GFAP) or were immersed in citric buffer (pH 6.0) and autoclaved
for 15 min at 121˚C. The protocol replicated that of PrP detection, with exception of 10 min
incubation in 98% formic acid.
Cell Counts and DAB Quantification
Ten serial sections from three GSS/101LL and three NBH/101LL mice at clinical stage pathol-
ogy from three anatomically distinct brain regions, the gigantocellular reticular (Gi) nucleus of
the brain stem, the retrosplenial granular cortex (RSGc), and the SNc were cut at anatomically
equivalent regions, approximately Bregma -6 mm (brain stem), Bregma -1.8 mm (cortex), and
Bregma -3 mm (midbrain).
Digital images were captured at x20 magnification using a Nikon E800 bright-field micro-
scope. A calibrated grid (100 x 100 μm) was overlaid onto each image, and the number of cell
bodies was determined by counting. The total number of cells counted in GSS/101LL brain
regions was then normalised to the region matched NBH/101LL controls and presented as the
percentage proportion of cells present in GSS/101LL compared to NBH/101LL.
DAB quantification was performed on ten serial low-magnification images (x4) of brain
stem, thalamus, cerebellum, and cortex, examining the total quantity of positive staining in
each section and averaging across the serial sections. DAB quantification was performed using
Image J and the colour deconvolution plug-in.
RT-QuIC Assay
Prnp DNA sequences encoding Syrian hamster residues 23 to 137 followed by sheep residues
141 to 234 of the R154 Q171 polymorph (accession number AY907689) (Ham/Shp chimeric
PrP) were prepared according to previous methods [20]. RT-QuIC buffer composition was as
follows: 10 mM phosphate buffer (pH 7.4), 130 mM NaCl, 10 μM Thioflavin T (ThT), 10 μM
EDTA, and a final concentration of 0.1 mg/mL recPrP. Ninety-eight μL of this master mix
were loaded onto black 96-well clear bottom plates (Nalgene Nunc International). Corre-
spondingly, 2 μL of diluted brain homogenate were added to each well for a final reaction vol-
ume of 100 μL. Each sample was run in triplicate, and included in each reaction were standard
positive controls (79A murine scrapie prion disease at a concentration of 0.1% [w/v] of the
original brain weight) and negative controls (uninfected murine brains at a concentration of
0.1% [w/v] of the original brain weight and RT-QuIC master mix–only samples). Plates were
then sealed with a plate sealer film (Nalgene Nunc International). A PolarSTAR Omega (BMG
Labtech) plate reader was used to incubate the samples at 42˚C for 60 h with cycles of 1 min
rest and 1 min 700 rpm double orbital shake. ThT fluorescence was then measured (450 nm
excitation/480 emission) every 15 min during the 60 h incubation.
PMCA Assay and Western Blot
PMCA experiments were performed following the amplification procedure described previ-
ously [56]. Briefly, aliquots of PMCA substrate, derived from transgenic mice P101L brains,
were incubated with PMCA seeds in 0.2-mL PCR tubes to a final volume of 120 μL. Serial
cycles of sonication and incubation were performed for 48 h at 37˚C, comprising 20 sec of son-
ication (at an amplitude of 38, wattage: 278–299) followed by 29 min 40 sec of incubation for
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each cycle (Qsonica, model Q-700). Detection of PrPres was assessed by PK treatment and
western blotting methodology previously described [56].
RNA Extraction
Brain stem, thalamus, cerebellum, and cortex were dissected from 6 GSS/101LL animals at ter-
minal illness and from 6 NBH/101LL age-matched mice. The tissue was weighed then homog-
enised in 1 mL Trizol (Life Technologies) per 100 mg of tissue. The homogenate was thus
centrifuged at 11,500x g for 10 min at 4˚C. The pellet was discarded. Chloroform (0.2 mL/mL
Trizol) was then added to cause phase separation, whereby protein constitutes the organic
phase, DNA the interphase, and RNA the aqueous phase after a 11,500x g centrifugal step for
15 min at 4˚C. The aqueous phase was transferred to fresh RNase-free tubes (Life Technolo-
gies). Isopropanol (0.5 mL/mL Trizol) was added and incubated for 10 min at room tempera-
ture. The RNA sample was then centrifuged for 10 min at 11,500x g at 4˚C. The RNA pellet
was washed in 75% ethanol (1 mL/mL Trizol) then centrifuged for 5 min at 8,000x g at 4˚C.
The RNA pellet was then resuspended in Nuclease Free dH2O (Life Technologies), aliquoted,
and stored at -80˚C.
Microarray
RNA was extracted from brain regions of individual animals. To remove non-disease–specific
inter-animal variation, each sample consisted of a pool of two animals for an individual brain
region. This resulted in 24 samples. Samples were subjected to transcriptomics analyses using
Mouse Gene 2.0 array run on a GeneTitan instrument (Affymetrix) by Edinburgh Genomics
(www.genomics.ed.ac.uk). Data were normalised using Affymetrix Expression Console soft-
ware and saved as an ‘.expression’ file containing a unique identifier for each transcript (gene
annotation concatenated to probe ID). In subsequent columns, gene and GO annotations
were included for assigning class-sets for the analysis of information contained in the network
graph, followed by the RMA-normalised raw data. The ‘.expression’ file is subsequently loaded
into the network analysis tool BioLayout Express3D [30], in which a pairwise Pearson correla-
tion matrix is calculated as a measure of similarity between transcript profiles. A network was
created using a threshold of r 0.95 and layout performed using modified Fruchterman–
Rheingold algorithm [57]. In this paradigm, each node represents a single transcript, which
are connected by weighted, undirected edges representing correlations above the threshold.
Groups of highly correlated transcripts were then “clustered” using the Markov cluster algo-
rithm [31]. To confirm the changed expression of transcripts between GSS and NBH/101LL
brain regions, data were filtered to include only transcripts annotated to known or predicted
genes. Each transcript was then tested for statistical significance. As data were not of equal var-
iance, as determined by Kolmogorov–Smirnov test, nonparametric Mann–Whitney U test
(p< 0.05) was performed to assess the change of each transcript intensity in a GSS/101LL
brain region compared to its respective NBH/101LL control brain region. Data were then fur-
ther filtered to include only those transcripts that showed a>1.5-fold change. Further analyses
were performed to include a “total” gene list for each GSS/101LL brain region using the same
statistical parameters outlined above. Genes in the resulting lists were then assigned likely cell
types of origin by inspecting their profile on an expression atlas of cell types on published
microarray analyses [32,33], including various types neuronal, glial, and myeloid cell popula-
tions. These data were loaded into BioLayout Express3D at a Pearson correlation cut-off of (r
0.7), and genes were assigned a putative cell type of origin based upon inspection of their
expression pattern across the cell atlas. Genes attributable to a microglia origin up-regulated in
all regions, regardless of the presence of pathology, were subjected to GO enrichment analysis.
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All the primary microarray data have been deposited in GEO: GSE74079.
Supporting Information
S1 ARRIVE checklist. Supporting ARRIVE guidelines checklist. Reporting of animal experi-
ments, which adhere to guidelines established for transparent and reproducibility of experi-
mental data.
(PDF)
S1 Data. Dataset with raw data used in Fig 1B.
(XLSX)
S2 Data. Dataset with raw data used in Fig 2A and 2B.
(XLSX)
S3 Data. Dataset with raw data used in Fig 4E and 4F.
(XLSX)
S4 Data. Dataset with raw data used in Fig 5A and 5B.
(XLSX)
S5 Data. Dataset with raw data used in Fig 6B.
(XLSX)
S6 Data. Dataset with raw data used in Fig 7A and 7B.
(XLSX)
S7 Data. Dataset with raw data used in S2 Fig.
(XLSX)
S1 Fig. PMCA confirms widespread detection of misfolded prion seeds beyond levels
detected using IHC. In vitro amplification potential of different brain regions from animals
inoculated with GSS and NBH controls (PMCA). GSS/101LL and the NBH/101LL seeds were
diluted 1:3 in fresh Tg-P101L substrate. (F) corresponds to the non-sonicated samples and (S)
to the sonicated (amplified) samples. vCJD (1/100) is used as a positive PMCA reaction con-
trol, and unseeded reactions are used as negative controls. Molecular mass of electrophoretic
markers is given in kilodaltons (kDa).
(TIF)
S2 Fig. Vacuolation quantification profile of GSS/101LL brain regions at clinical stage
pathology. Vacuolation profile of GSS/101LL clinical stage animals (n = 9). Grey matter scores
(medulla [brain stem], cerebellum, superior colliculus [midbrain], hypothalamus, thalamus,
hippocampus, septum, retrospinal cortex, and cingulate and motor cortices) are scored blind
on a scale of 0–5, whereby 5 represents severe vaculation and 0 represents no vacuolation.
(TIF)
S1 Table. The data in this table have been constructed by assessing the gene expression
changes at clinical stages of disease (291.11 ± 5.29 dpi) between GSS/101LL individual
brain regions compared to their respective NBH/101LL brain regions. The average (mean)
change in gene expression was tested for statistical significance using the Mann–Whitney U
test, and any data that showed higher than p = 0.05 were filtered out of our analysis. Further-
more, we then assessed the fold change of the average gene expression changes, and any data
that had a fold change of less than 1.5 were filter out of our analysis. This resulted in "total"
lists of differential expressed genes (up- and down-regulated) from each brain region in GSS/
101LL mice compared to their respective NBH/101LL controls. In total, this resulted in 3,685
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differential regulated genes in brain stem (1,516 up/2,169 down), 1,521 differential regulated
genes in thalamus (587 up/934 down), 3,540 differential regulated genes in cerebellum (1,668
up/1,872 down), and 384 differential regulated genes in cortex (112 up/272 down). To further
annotate the data, every up-regulated or down-regulated gene identified has been overlaid
onto gene expression analysis from isolated cell populations performed in previous studies
[32,33]. The overlaid gene lists are then input into BioLayout Express3D software set at a Pear-
son correlation cut-off of r 0.7. This allows genes to be grouped together based upon their
differential expression between cell types isolated in previous studies [32,33]. Once we have
accumulated data in BioLayout Express3D that can be attributed to specific cell types, we then
simplified the nomenclature to fit genes into broad cell type terms. For example, a number of
different neuronal cell populations have been assessed by Doyle et al. ranging from Purkinje
cells of the cerebellum to cholinergic neurons of the striatum. In this study, however, all genes
that can be assigned to any neuronal population have been attributed the cellular origin of neu-
ronal. We also had instances whereby genes would be expressed in cells of both neuronal ori-
gin and either astrocytes and/or oligodendrocytes. In these cases, we termed the cellular origin
neuronal and glia mix. Please note the following: (i) It is relatively uncommon, but some genes
in each list may have duplicates; therefore the numbers of differential regulated genes isn’t
exact. (ii) The cell attribution data are gathered by groups of genes requiring a relatively high
correlation; this means that there will be individual genes whose gene expression data highly
correlate with others within the gene lists and therefore are not accounted for in our analysis.
In these instances, these genes are assigned N/A, although it is important to note that, despite
this, these genes could well be expressed by cell types represented in this analysis. Our analysis
offers up a prediction based upon experimental evidence from previous published studies. (iii)
Some genes in each gene list have been attributed to be of an "other" cell type. This means that
in our analysis, there were groups of genes that showed high correlation with one another, but
their gene expression was not indicative of being expressed in any of the cell types onto which
we overlapped our data. This does not mean that they are definitely not expressed by any of
these cells types, but that we could not assign these genes using the information available to us.
This could mean either that their expression belongs to a different cell type present in the CNS
or one that invades the CNS during disease or that they are expressed as part of a cellular
response mechanism (e.g., autophagy, ER stress, etc.), which was not exhibited in the datasets
which we overlaid our data onto.
(XLSX)
S2 Table. GO enrichment analysis of genes not directly associated with neurodegeneration.
In sheet 1 "GO enrichment," the data presented are constructed by inputting microglial genes
that are up-regulated in GSS/101LL cerebellum (see S1 Table) into DAVID. The GO terms
were then filtered, firstly for statistical significance by omitting all GO terms with a p-value less
than 0.03. Next, any GO term with less than a count of ten were omitted from analysis. This
resulted in a GO enrichment table of 79 GO terms. A number of common GO terms appeared
from the "GO enrichment" sheet, including but not restricted to homeostatic process, immune
system process, and metabolic process. However, it was noted that groups of related GO terms
(e.g., homeostatic process, cellular homeostasis, chemical homeostasis) shared similar or iden-
tical gene lists. Therefore, the genes used to construct each related group of GO terms were
plotted into a single gene list, and the replication of genes was then deleted; these data can be
viewed in sheet 2 "GO summary." Overall, it was found that almost half of the genes up-regu-
lated in microglia in GSS/101LL cerebellum were related to metabolic process (~31%) or
homeostasis (~18%). Please note the following: (i) many of the genes (~22%) that were shown
to be up-regulated in microglia in GSS/101LL cerebellum were not assigned to GO terms and
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therefore are described as "non-attributed genes," and (ii) there are genes that are assigned
under multiple and distinct GO terms, and therefore two separate gene lists in "GO summary"
may exhibit some overlapping genes.
(XLSX)
S3 Table. GO enrichment analysis of genes directly associated with neurodegeneration. In
sheet 1 "GO enrichment," the data presented are constructed by inputting microglial genes
that are up-regulated in GSS/101LL brain stem and thalamus but that are not up-regulated in
GSS/101LL cerebellum (see S1 Table) into DAVID. The GO terms were then filtered, firstly
for statistical significance by omitting all GO terms with a p-value less than 0.03. Next, any GO
term with less than a count of ten were omitted from analysis. This resulted in a GO enrich-
ment table of 155 GO terms. A number of common GO terms appeared from the "GO enrich-
ment" sheet, including but not restricted to immune system process, cell activation, cell
proliferation, and metabolic process. However, it was noted that groups of related GO terms
(e.g., immune system process, immune response, positive regulation of immune response)
shared similar or identical gene lists. Therefore, the genes used to construct each related group
of GO terms were plotted into a single gene list, and the replication of genes was then deleted;
these data can be viewed in sheet 2 "GO summary." Overall, it was found that almost half of
the genes up-regulated in microglia that are associated with neurodegeneration were related to
metabolic process (~26%) or immune activation (~21%). Please note the following: (i) many of
the genes (~19%) that were shown to be up-regulated were not assigned to GO terms and
therefore are described as "non-attributed genes" and (ii) there are genes that are assigned
under multiple and distinct GO terms, and therefore two separate gene lists in "GO summary"
may exhibit some overlapping genes.
(XLSX)
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